RNA News

Latest RNA News

• Cantor Fitzgerald Reaffirms Their Buy Rating on Atrium Therapeutics, Inc. (RNA)
  TipRanks Auto-Generated Intelligence Newsdesk · Oct 15, 2026
• Moderna Stock (MRNA) Climbs 13% to Top Its 52-Week High — Here’s Why
  Solomon Oladipupo · Oct 9, 2026
• Vertex and Moderna Advance CF mRNA Therapy: What VX-522 Trial Completion Means for Investors
  TipRanks Clinical-Trials-Auto-Generated Newsdesk · Oct 9, 2026
• Alterity Therapeutics to Present at Canaccord Genuity Drug and Device Conference
  TipRanks Australian Auto-Generated Newsdesk · Oct 9, 2026
• RBC Capital Remains a Hold on Moderna (MRNA)
  TipRanks Auto-Generated Intelligence Newsdesk · Oct 9, 2026
• AI Predicted Novartis’ $30 Billion Drug Failure. Are Biogen and Takeda Next?
  Ran Melamed · Oct 7, 2026
• Why Is Moderna Stock (MRNA) Falling Today, October 6?
  Solomon Oladipupo · Oct 6, 2026
• Alterity’s ATH434 Phase 2 Data Strengthen Case for MSA Phase 3 Trial
  TipRanks Australian Auto-Generated Newsdesk · Oct 4, 2026
• ADPT, MRNA, CRWV, NBIS, JAZZ trending with analysts
  TipRanks Weekend Auto-Generated Newsdesk · Oct 3, 2026
• Why Did Moderna Stock Gain (MRNA) in After-Hours Trading on Thursday?
  Shalu Saraf · Oct 2, 2026
• Moderna appoints COO as oncology expansion accelerates
  TipRanks Auto-Generated Newsdesk · Sep 30, 2026
• Wall Street Analysts Are Bullish on Top Healthcare Picks
  TipRanks Newsroom · Sep 29, 2026
• Cartesian Therapeutics Reports Encouraging Descartes-08 Retreatment Data
  TipRanks Auto-Generated Newsdesk · Sep 29, 2026
• Why the S&P 500 Could Still Reach New Highs despite 5% Treasuries
  Bernard Zambonin · Sep 27, 2026
• 3 Vanguard ETFs Flying Under the Radar with 20% Upside
  Kirti Tak · Sep 25, 2026
• Moderna (MRNA) Receives a Hold from Bernstein
  TipRanks Auto-Generated Intelligence Newsdesk · Sep 25, 2026
• Alterity Therapeutics Sets 2026 AGM Date and Director Nomination Deadline
  TipRanks Australian Auto-Generated Newsdesk · Sep 25, 2026
• Analysts Have Conflicting Sentiments on These Healthcare Companies: Pyxis Oncology (PYXS), Moderna (MRNA) and Eli Lilly & Co (LLY)
  TipRanks Newsroom · Sep 22, 2026
• Why Is Moderna Stock (MRNA) Soaring Today, September 21?
  Solomon Oladipupo · Sep 21, 2026
• Alterity Therapeutics to Spotlight MSA Program at ASX SMIDcaps Conference
  TipRanks Australian Auto-Generated Newsdesk · Sep 17, 2026